Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Barclays Keeps Their Hold Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)

Tipranks - Tipranks - Wed Jan 28, 2:40AM CST

Barclays analyst Hassan Al-Wakeel maintained a Hold rating on Fresenius Medical Care AG & Co. KGaA today and set a price target of €47.50.

Claim 50% Off TipRanks Premium

Al-Wakeel covers the Healthcare sector, focusing on stocks such as Smith & Nephew, Straumann Holding AG, and EssilorLuxottica SA. According to TipRanks, Al-Wakeel has an average return of 0.5% and a 50.00% success rate on recommended stocks.

In addition to Barclays, Fresenius Medical Care AG & Co. KGaA also received a Hold from Deutsche Bank ‘s Falko Friedrichs in a report issued yesterday. However, on the same day, Bank of America Securities reiterated a Sell rating on Fresenius Medical Care AG & Co. KGaA (LSE: 0H9X).

See Insiders’ Hot Stocks on TipRanks >>

Based on Fresenius Medical Care AG & Co. KGaA’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of €4.88 billion and a net profit of €274.8 million. In comparison, last year the company earned a revenue of €4.76 billion and had a net profit of €213.03 million

Read More on GB:0H9X:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).